The European Union’s drug regulator said on Friday there is a possible link between rare cases of bloods clots in deep veins with Johnson & Johnson’s COVID-19 vaccine and recommended the condition be listed as a side-effect of the shot.
The European Medicines Agency also recommended immune thrombocytopenia (ITP), a bleeding disorder caused by the body mistakenly attacking platelets, be added as an adverse reaction with an unknown frequency to the J&J vaccine product information and to AstraZeneca’s vaccine.
Surgical patients who had COVID-19 more likely to develop fatal blood clots: StudySurgical patients who recently contracted a COVID-19 infection are at a higher risk of developing fatal blood clots after surgery, a new study finds. ... Coronavirus
Blood clot risk much higher from COVID-19 than with vaccines: UK studyCOVID-19 patients face a much higher risk of developing blood clots than those vaccinated with AstraZeneca Plc or Pfizer Inc.’s shots, according to a ... Coronavirus
J&J says COVID-19 booster dose increased antibodies in early-stage trialsA booster dose of Johnson & Johnson’s COVID-19 vaccine sharply increased levels of antibodies against the coronavirus, according to interim data from ... Coronavirus